Drug approved for patients with ALK-positive, early-stage cancer who undergo surgery to remove their tumor
MONDAY, April 22, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
The approval was based on positive results from the phase 3 ALINA study that showed Alecensa reduced the risk for disease recurrence or death (hazard ratio, 0.24) versus platinum-based chemotherapy in patients with completely resected IB (tumor ≥4 cm) to IIIA ALK-positive NSCLC. An exploratory analysis showed an improvement of central nervous system disease-free survival (hazard ratio, 0.22). No unexpected safety findings emerged.
“The approval of Alecensa marks a pivotal moment for people newly diagnosed with early-stage ALK-positive lung cancer, who until now, were not able to receive ALK-specific therapy,” Ken Culver, from ALK Positive Inc., said in a statement. “Now, with this significant advance, it is more important than ever that all people diagnosed with early-stage lung cancer undergo testing for ALK and other recommended biomarkers to receive the treatment most appropriate for them.”
Approval of Alecensa was granted to Genentech.
Gene Mutation Identified That Increases Lung Cancer Risk 
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC 
Lung Transplant Can Prolong Survival in Stage IV NSCLC 
Risk-Based Strategies Superior to USPSTF Criteria for Lung Cancer Screening 
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer 
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026 
U.S. Adults May Not Understand Their Risk for Vascular Disease 
Autism Spectrum Disorder Diagnoses Increased for Females Since 2020 
.jpg)
